Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca CEO Soriot says to work with new chairman for many years

Published 29/07/2022, 12:48
Updated 29/07/2022, 13:02
© Reuters. FILE PHOTO: Pascal Soriot, chief executive of pharmaceuticals company AstraZeneca, attends an interview with Reuters in Shanghai, China,  November 4, 2019. REUTERS/Brenda Goh/File Photo

© Reuters. FILE PHOTO: Pascal Soriot, chief executive of pharmaceuticals company AstraZeneca, attends an interview with Reuters in Shanghai, China, November 4, 2019. REUTERS/Brenda Goh/File Photo

FRANKFURT (Reuters) - Long-serving AstraZeneca (NASDAQ:AZN) boss Pascal Soriot said on Friday he expects to work with the new chairman-designate of the London-listed drugmaker, who will take over in 2023, for many years to come, suggesting he is not ready to retire.

© Reuters. FILE PHOTO: Pascal Soriot, chief executive of pharmaceuticals company AstraZeneca, attends an interview with Reuters in Shanghai, China,  November 4, 2019. REUTERS/Brenda Goh/File Photo

The company said on Friday that Michel Demare will take over from outgoing Chairman Leif Johansson, who, like Soriot, has been in his leadership position for about a decade.

"Michel and I will be working together and forming an excellent team for the many years to come," Soriot said on an analyst call after the company released its quarterly results.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.